Scholarlink

Purpose <p>PCOS is a complex endocrine condition with various hallmarks like menstrual abnormalities, hyperandrogenism, and the appearance of several little cysts in one or both ovaries. It is linked to serious metabolic and reproductive dysfunctions and its worldwide prevalence, according on diagnostic standards, ranges from 8 to 13%. Prevalence rates are said to be greater in South Asia range between 20 and 33%. The creation of rutin-containing sustained-release microspheres using different polymeric carriers is the subject of more current research efforts. A naturally occurring flavonoid, rutin is known for its antioxidant, anti-inflammatory, and hypoglycaemic qualities. The therapeutic potential of rutin in its sustained-release form is particularly intriguing because PCOS is frequently associated with oxidative stress, hormonal abnormalities, and dyslipidaemia.</p> Methods <p>The limited therapeutic use of rutin against PCOS is caused by its low water solubility and frequent breakdown. Rutin-loaded polymeric microspheres were created using a solvent evaporation technique to overcome these difficulties. The stability, drug release kinetics, encapsulation efficiency, and particle size of the microspheres were assessed. Improved bioavailability was confirmed by in vivo pharmacokinetic investigations, but in vitro release trials demonstrated a sustained and controlled release profile.</p> Results <p>At 260&#xa0;nm, hydroxypropyl propyl methylcellulose-loaded rutin microspheres (HPMC-RUT-MS) had the highest absorption in the UV region. The synthetic microspheres were 58.9&#xa0;μm in size and had a spherical form, according to the SEM picture. The drug release from Batch F4 was 72.54% following an 8-hour in vitro trial. The histopathological evaluation showed significant histological improvement, including fewer cystic follicles and more developing follicles, was also observed in the rutin-treated group (d) in comparison to the PCOS group.</p> Conclusion <p>The customized microspheres have demonstrated great potential for the treatment of metabolic disorders, including PCOS, by maintaining stable plasma levels of rutin. This discovery paves the way for the development of polymer-based rutin delivery systems, which might lead to improved outcomes for chronic disease treatments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Polymeric Microspheres for Sustained Delivery of Rutin in the Management of PCOS

  • 期刊论文

  • 发表日期：

    2025年10月24日

查看全文
  • Monalisa Roy,
  • Rupa Mazumder,
  • Neelam Singh,
  • Anmol Dogra,
  • Rakhi Mishra

摘要

Purpose

PCOS is a complex endocrine condition with various hallmarks like menstrual abnormalities, hyperandrogenism, and the appearance of several little cysts in one or both ovaries. It is linked to serious metabolic and reproductive dysfunctions and its worldwide prevalence, according on diagnostic standards, ranges from 8 to 13%. Prevalence rates are said to be greater in South Asia range between 20 and 33%. The creation of rutin-containing sustained-release microspheres using different polymeric carriers is the subject of more current research efforts. A naturally occurring flavonoid, rutin is known for its antioxidant, anti-inflammatory, and hypoglycaemic qualities. The therapeutic potential of rutin in its sustained-release form is particularly intriguing because PCOS is frequently associated with oxidative stress, hormonal abnormalities, and dyslipidaemia.

Methods

The limited therapeutic use of rutin against PCOS is caused by its low water solubility and frequent breakdown. Rutin-loaded polymeric microspheres were created using a solvent evaporation technique to overcome these difficulties. The stability, drug release kinetics, encapsulation efficiency, and particle size of the microspheres were assessed. Improved bioavailability was confirmed by in vivo pharmacokinetic investigations, but in vitro release trials demonstrated a sustained and controlled release profile.

Results

At 260 nm, hydroxypropyl propyl methylcellulose-loaded rutin microspheres (HPMC-RUT-MS) had the highest absorption in the UV region. The synthetic microspheres were 58.9 μm in size and had a spherical form, according to the SEM picture. The drug release from Batch F4 was 72.54% following an 8-hour in vitro trial. The histopathological evaluation showed significant histological improvement, including fewer cystic follicles and more developing follicles, was also observed in the rutin-treated group (d) in comparison to the PCOS group.

Conclusion

The customized microspheres have demonstrated great potential for the treatment of metabolic disorders, including PCOS, by maintaining stable plasma levels of rutin. This discovery paves the way for the development of polymer-based rutin delivery systems, which might lead to improved outcomes for chronic disease treatments.